RT Journal Article
SR Electronic
T1 Covasim: an agent-based model of COVID-19 dynamics and interventions
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.10.20097469
DO 10.1101/2020.05.10.20097469
A1 Cliff C. Kerr
A1 Robyn M. Stuart
A1 Dina Mistry
A1 Romesh G. Abeysuriya
A1 Katherine Rosenfeld
A1 Gregory R. Hart
A1 Rafael C. Núñez
A1 Jamie A. Cohen
A1 Prashanth Selvaraj
A1 Brittany Hagedorn
A1 Lauren George
A1 Michał Jastrzębski
A1 Amanda Izzo
A1 Greer Fowler
A1 Anna Palmer
A1 Dominic Delport
A1 Nick Scott
A1 Sherrie Kelly
A1 Carrie Bennette
A1 Bradley Wagner
A1 Stewart Chang
A1 Assaf P. Oron
A1 Edward Wenger
A1 Jasmina Panovska-Griffiths
A1 Michael Famulare
A1 Daniel J. Klein
YR 2021
UL http://medrxiv.org/content/early/2021/02/11/2020.05.10.20097469.abstract
AB The COVID-19 pandemic has created an urgent need for models that can project epidemic trends, explore intervention scenarios, and estimate resource needs. Here we describe the methodology of Covasim (COVID-19 Agent-based Simulator), an open-source model developed to help address these questions. Covasim includes country-specific demographic information on age structure and population size; realistic transmission networks in different social layers, including households, schools, workplaces, long-term care facilities, and communities; age-specific disease outcomes; and intrahost viral dynamics, including viral-load-based transmissibility. Covasim also supports an extensive set of interventions, including non-pharmaceutical interventions, such as physical distancing and protective equipment; pharmaceutical interventions, including vaccination; and testing interventions, such as symptomatic and asymptomatic testing, isolation, contact tracing, and quarantine. These interventions can incorporate the effects of delays, loss-to-follow-up, micro-targeting, and other factors. Implemented in pure Python, Covasim has been designed with equal emphasis on performance, ease of use, and flexibility: realistic and highly customized scenarios can be run on a standard laptop in under a minute. In collaboration with local health agencies and policymakers, Covasim has already been applied to examine epidemic dynamics and inform policy decisions in more than a dozen countries in Africa, Asia-Pacific, Europe, and North America.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approval not required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and source code are available; details are available in the manuscript.